%0 Journal Article
%T A comprehensive review of BET-targeting PROTACs for cancer therapy.
%A Zhou XL
%A Zhao F
%A Xu YT
%A Guan YY
%A Yu T
%A Zhang YZ
%A Duan YC
%A Zhao Y
%J Bioorg Med Chem
%V 73
%N 0
%D Sep 2022 29
%M 36202064
%F 3.461
%R 10.1016/j.bmc.2022.117033
%X Targeted protein degradation using proteolysis-targeting chimeras (PROTACs) has emerged as an effective strategy for drug discovery, given their unique advantages over target protein inhibition. The bromodomain and extra-terminal (BET) family proteins play a key role in regulating oncogene expression and are considered attractive therapeutic targets for cancer therapy. Considering the therapeutic potential of BET proteins in cancer and the marked attractiveness of PROTACs, BET-targeting PROTACs have been extensively pursued. Recently, BET-targeting PROTACs based on new E3 ligases and novel strategies, such as light-activated, macrocyclic, folate-caged, aptamer-PROTAC conjugation, antibody-coupling, and autophagy-targeting strategies, have emerged. In the present review, we provide a comprehensive summary of advances in BET-targeting PROTACs.